Entia Biosciences (ERGO) 10-K 14 Apr 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Apr. 13, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Entia Biosciences, Inc.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		28,134,777
Entity Public Float			$ 1,663,019
Amendment Flag	false
Entity Central Index Key	1,408,299
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 24,133	$ 99,462
Accounts receivable, net	7,098	243,782
Inventory, net	40,323	48,043
Prepaid expenses	56,782	46,107
Total Current Assets	128,336	437,394
Property and Equipment, net	32,686	43,147
Patents and licenses, net	232,584	342,834
Long-Term Inventory	55,000	47,333
Total Assets	448,606	870,708
Current Liabilities:
Accounts payable and accrued expenses	960,557	552,990
Line of credit	58,195	16,179
Short-term convertible notes payable, net of discount related-party	0	9,399
Short-term convertible notes payable, net of discount	181,981	357,646
Notes payable	39,061	51,030
Total Current Liabilities	1,239,794	987,244
Total Liabilities	1,239,794	987,244
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized, Series A preferred stock, 350,000 shares designated, 191,307 and 200,807 shares issued and outstanding, respectively, aggregate liquidation value of $956,535 and $1,004,035 respectively	191	201
Common stock, $0.001 par value, 150,000,000 shares authorized, 28,107,337 and 15,512,927 shares issued and outstanding, respectively	28,108	15,514
Additional paid-in capital	12,309,450	10,771,035
Deferred compensation	(51,945)	(86,344)
Accumulated deficit	(13,076,992)	(10,816,942)
Total Stockholders' Equity (Deficit)	(791,188)	(116,536)
Total Liabilities and Stockholders' Equity (Deficit)	$ 448,606	$ 870,708

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	28,107,337	15,512,927
Common stock, shares outstanding	28,107,337	15,512,927
Series A Preferred Stock [Member]
Preferred stock, shares authorized	350,000	350,000
Preferred stock, shares issued	191,307	200,807
Preferred stock, shares outstanding	191,307	200,807
Preferred stock, aggregate liquidation value (in Dollars)	$ 956,535	$ 1,004,035

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
REVENUES	$ 346,910	$ 656,342
COST OF GOODS SOLD	131,007	245,471
GROSS PROFIT	215,903	410,871
OPERATING EXPENSES
Advertising and promotion	127,127	125,728
Professional fees	231,125	156,561
Consulting fees	344,112	400,352
Impairment of licenses	110,000	27,080
General and administrative	1,429,495	1,499,164
Total Operating Expenses	2,241,859	2,208,885
LOSS FROM OPERATIONS	(2,025,956)	(1,798,014)
OTHER INCOME (EXPENSES)
Interest expense	(149,284)	(339,709)
Other income (expense)	(35,895)	7,298
Loss on write-off of debt discount	(23,321)	(100,000)
Loss on settlement/conversion of notes payable	(32,500)	(169,187)
Gain on settlement of accounts payable	6,906	103,021
NET LOSS	$ (2,260,050)	$ (2,296,591)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED: (in Dollars per share)	$ (0.09)	$ (0.24)
Weighted common shares outstanding - basic and diluted (in Shares)	24,289,381	9,442,352

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Conversion of Convertible Debt [Member]Common Stock [Member]	Conversion of Convertible Debt [Member]Additional Paid-in Capital [Member]	Conversion of Convertible Debt [Member]Retained Earnings [Member]	Preferred Stock [Member]Conversion of Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]Conversion of Accounts Payable [Member]	Common Stock [Member]Conversion of Accrued Compensation [Member]	Common Stock [Member]Stock Issued for Future Services [Member]	Common Stock [Member]Conversion of Warrants [Member]	Common Stock [Member]Conversion of Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Warrants Issued for Convertible Notes [Member]	Additional Paid-in Capital [Member]Conversion of Accounts Payable [Member]	Additional Paid-in Capital [Member]Conversion of Accrued Compensation [Member]	Additional Paid-in Capital [Member]Stock Issued for Future Services [Member]	Additional Paid-in Capital [Member]Warrants Issued for Conversion of Accrued Salary [Member]	Additional Paid-in Capital [Member]Warrants Issued for Services [Member]	Additional Paid-in Capital [Member]Conversion of Warrants [Member]	Additional Paid-in Capital [Member]Conversion of Preferred Stock [Member]	Additional Paid-in Capital [Member]	Deferred Compensation, Share-based Payments [Member]Stock Issued for Future Services [Member]	Deferred Compensation, Share-based Payments [Member]Warrants Issued for Services [Member]	Deferred Compensation, Share-based Payments [Member]	Stock Subscriptions [Member]	Retained Earnings [Member]Warrants Issued for Convertible Notes [Member]	Retained Earnings [Member]Conversion of Accounts Payable [Member]	Retained Earnings [Member]Conversion of Accrued Compensation [Member]	Retained Earnings [Member]Warrants Issued for Conversion of Accrued Salary [Member]	Retained Earnings [Member]Warrants Issued for Services [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2013					$ 282						$ 8,298									$ 7,793,760			$ (182,576)	$ (8,520,351)						$ (949,587)
Balance (in Shares) at Dec. 31, 2013					281,969						8,297,645
Issuance of warrants												$ 88,600				$ 91,863	$ 153,010					$ (153,010)			$ 88,600			$ 91,863
Amortization of deferred compensation																							293,492							293,492
Net loss																								(2,296,591)						(2,296,591)	$ (2,296,591)
Beneficial conversion feature in connection with convertible notes payable																				188,300										188,300
Issuance of common stock for cash											$ 525									224,475										225,000
Issuance of common stock for cash (in Shares)											525,000
Issuance of common stock for conversion of securities	$ 2,634	$ 930,650	$ 933,284	$ (81)		$ 345	$ 2,592			$ 812			$ 132,583	$ 775,178					$ (731)							$ 132,928	$ 777,770
Issuance of common stock for conversion of securities (in Shares)	2,633,579			(81,162)		344,530	2,592,570			811,620
Stock compensation																				227,570										227,570
Issuance of common stock for services								$ 68			$ 240				$ 44,182					121,595	$ (44,250)									121,835
Issuance of common stock for services (in Shares)								68,283			239,700
Receipt of stock subscription receivable, less write-off of $9,000																														49,000
Balance at Dec. 31, 2014					$ 201						$ 15,514									10,771,035			(86,344)	(10,816,942)						(116,536)	(116,536)
Balance (in Shares) at Dec. 31, 2014					200,807						15,512,927
Issuance of warrants												$ 10,000					$ 7,891								$ 10,000				$ 7,891
Amortization of deferred compensation																							102,288							102,288
Deferral of offering fees																				(26,700)										(26,700)
Net loss																								(2,260,050)						(2,260,050)	(2,260,050)
Issuance of common stock for cash											$ 5,348									554,825										560,173
Issuance of common stock for cash (in Shares)											5,347,901
Issuance of common stock for conversion of securities	$ 3,069	$ 318,632	$ 321,701	$ (10)		$ 554			$ 2,051	$ 95			$ 130,054					$ (2,051)	$ (85)							$ 130,608
Issuance of common stock for conversion of securities (in Shares)	3,068,882			(9,500)		554,521			2,050,923	95,000
Stock compensation											$ 1,550									555,394										556,944
Stock compensation (in Shares)											1,550,000
Cancellation of shares issued to executives as compensation											$ (1,000)									(199,000)										(200,000)
Cancellation of shares issued to executives as compensation (in Shares)											(1,000,000)
Issuance of common stock for services											$ 927									121,566										122,493
Issuance of common stock for services (in Shares)											927,183
Balance at Dec. 31, 2015					$ 191						$ 28,108									$ 12,309,450			$ (51,945)	$ (13,076,992)						$ (791,188)	$ (791,188)
Balance (in Shares) at Dec. 31, 2015					191,307						28,107,337

CONSOLIDATED STATEMENT OF STOC6

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)	12 Months Ended
	Dec. 31, 2014USD ($)
Stock Subscriptions [Member]
Stock subscription receivable, write-off	$ 9,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS USED IN OPERATING ACTIVITIES:
Net loss	$ (2,260,050)	$ (2,296,591)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	0	30,022
Depreciation/amortization	31,996	38,047
Gain on settlement of accounts payable	(6,906)	(103,021)
Impairment of licenses	110,000	27,080
Loss on write-off of debt discount	23,321	100,000
Amortization of discount on convertible notes	113,937	120,387
Loss on conversion of notes payable	32,500	169,187
Stock-based compensation	589,616	642,897
Loss on sale of stock subscription receivable	0	12,965
Changes in operating assets and liabilities:
Accounts receivable	236,684	(262,607)
Inventory	53	43,565
Prepaid expenses	38,507	31,668
Accounts payable and accrued expenses	553,777	766,117
NET CASH USED IN OPERATING ACTIVITIES	(536,565)	(680,284)
CASH FLOWS USED IN INVESTING ACTIVITIES:
Purchase of property and equipment	(8,051)	(4,607)
Acquisition of patents and patents pending (net)	(13,235)	(40,857)
NET CASH USED IN INVESTING ACTIVITIES	(21,286)	(45,464)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	560,173	225,000
Proceeds from convertible notes payable and notes payable	100,000	591,500
Payment on notes payable	(177,651)	(43,176)
Payment on convertible note payable - related party	0	(40,000)
Proceeds from sale of stock subscription receivable	0	40,000
Proceeds from convertible note payable-related party	0	15,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	482,522	788,324
NET CHANGE IN CASH	(75,329)	62,576
Cash at beginning of period	99,462	36,886
Cash at end of period	24,133	99,462
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	37,834	843
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Issuance of note payable for insurance	0	43,313
Issuance of warrants for accrued salary	0	91,863
Stock Issued for Accounts Payable [Member]
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Stock issued	130,608	132,928
Covnersion of Convertible Notes Payable and Acrrued Interest [Member]
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Conversion of convertible notes payable, accounts payable and accrued interest to preferred and common stock	321,701	1,711,054
Stock Issued for Services Rendered [Member]
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Stock issued	$ 122,493	$ 0

NOTE 1 - ORGANIZATION AND OPERA

NOTE 1 - ORGANIZATION AND OPERATIONS	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – ORGANIZATION AND OPERATIONS Entia Biosciences, Inc. (“We” or “the Company”) engage in the development, production and distribution of organic dietary nutraceutical supplement products, principally in the United States of America. We are also engaged in the discovery, scientific evaluation and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics and other products developed and sold by Entia and by third parties. We have a history of incurring net losses and net operating cash flow deficits. We are also developing new organic medical foods products. At December 31, 2015, we had cash and cash equivalents of $24,133. These conditions raise substantial doubt about our ability to continue as a going concern. Based on our cash on hand, planned financings, and results from future operations, we believe that we will have sufficient funds to continue operations through 2016. In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we will likely be required to obtain capital from external sources, increase revenues and reduce operating costs. The issuance of equity securities will cause dilution to our shareholders. If external sources of financing are not available or are inadequate to fund our operations, we will be required to reduce operating costs including personnel costs, which could jeopardize our future strategic initiatives and business plans. The accompanying consolidated financial statements have been prepared assuming that the Company continues as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and principles of consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of Entia and Total Nutraceutical Solutions, a wholly-owned subsidiary, as of December 31, 2015 and 2014. Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents. Accounts receivable Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable. Outstanding account balances are reviewed individually for collectibility. We determine the allowance based on historical write-off experience, customer specific facts and economic conditions. Bad debt expense is included in general and administrative expenses, if any. We generally consider accounts greater than 30 days old to be past due. Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $5,736 and $30,022 at December 31, 2015 and 2014, respectively. Inventory Inventory consists of finished goods and raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the average cost method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory. The portion of inventory that is not expected to be used in production of our products for more than 12 months is a long-term asset. Property and equipment Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement Patents Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs. Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts. Licenses Licenses that allow us to use certain technology in the production of our products are amortized on a straight-line basis over their remaining useful life (typically 15-17 years). Long-lived assets, including licenses, property and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. We have recorded an impairment on our licenses in the amount of $110,000 and $27,080 on December 31, 2015 and 2014, respectively. Discount on convertible notes payable We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument. The amortization is recorded as interest expense on the consolidated statement of operations. Fair value of financial instruments The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable approximate their fair values determined based on level 1 inputs in the fair value hierarchy because of the short maturity of these instruments. Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes. Fair value measurements We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions. We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at December 31, 2015 or 2014, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the years ended December 31, 2015 and 2014. Revenue recognition We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured. Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers and distributors. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive. Allowances for product returns, primarily in connection with one distribution agreement, are provided at the time the sale is recorded. This allowance is based upon historical return rates for the Company and relevant industry patterns, which reflects anticipated returns of unopened product in its original packaging to be received over a period of 120 days following the original sale. Shipping and handling costs Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred. In 2015 and 2014, we incurred $27,848 and $34,286, respectively, in shipping costs included in cost of goods sold. Advertising costs Costs associated with the advertising of our products are expensed as incurred. Research and development Research and development costs are charged to expense as incurred. Research and development costs consist primarily of material and testing costs for research and development as well as research and development arrangements with unrelated third party research and development institutions. These research and development arrangements usually involve one specific research and development project. We may make non-refundable advances upon signing of these arrangements. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or as the related services are performed. Management periodically evaluates whether the goods will be delivered or services will be rendered. If management does not expect the goods to be delivered or services to be rendered, the capitalized advance payment is charged to expense. Research and development expense was $ 73,394 Equity instruments issued to parties other than employees for acquiring goods or services We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. Currently such transactions are primarily awards of warrants to purchase common stock. The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The assumptions used to determine the fair value of our warrants are as follows: - The expected life of warrants issued represents the period of time the warrants are expected to be outstanding. - The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant. - The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant. - The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant. During 2015 and 2014, we issued restricted common stock, warrants and non-statutory stock options to attorneys, scientific, marketing and financial consultants and our external contract accountants. The value of these instruments equal $384,922 of the total $589,616 for 2015 and $257,689 of the total $642,897 for 2014. Income taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. The tax years that are open to examination are 2012, 2013, 2014 and 2015. Net loss per common share Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2015 and 2014. The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2015 2014 Numerator: Net loss allocable to common stockholders $ (2,260,050 ) $ (2,296,591 ) Denominator: Weighted-average common shares outstanding 24,289,381 9,442,352 Basic and diluted net loss per share $ (0.09 ) $ (0.24 ) Common stock warrants 18,925,825 7,110,701 Series A convertible preferred stock 1,913,070 2,008,070 Stock options 2,898,220 2,866,470 Convertible debt including interest 601,775 1,317,604 Excluded dilutive securities 24,338,890 13,302,845 Reclassifications Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation. Segments We have determined that we operate in one segment for financial reporting purposes. Recently issued accounting pronouncements In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia in the first quarter of 2018, and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.

NOTE 3 - INVENTORY

NOTE 3 - INVENTORY	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 3 – INVENTORY Inventory consists of the following at: December 31, 2015 December 31, 2014 Raw materials $ 27,313 $ 202,591 Finished goods 219,074 43,849 246,387 246,440 Less reserve for excess and obsolete inventory (151,064 ) (151,064 ) 95,323 95,376 Less current portion (40,323 ) (48,043 ) $ 55,000 $ 47,333

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment, stated at cost, consists of the following at: December 31, 2015 December 31, 2014 Office equipment $ 31,658 $ 27,507 Production equipment 90,899 86,999 Leasehold improvements 16,328 16,328 138,885 130,834 Less: accumulated depreciation (106,199 ) (87,687 ) $ 32,686 $ 43,147 Depreciation expense was $18,512 and $23,605 for the years ended December 31, 2015 and 2014, respectively.

NOTE 5 - PATENTS AND LICENSES,

NOTE 5 - PATENTS AND LICENSES, NET	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 5 – PATENTS AND LICENSES, NET Our identifiable long-lived intangible assets are patents and licenses. During 2015 and 2014, management analyzed our intangibles for possible impairment. We have recorded for 2015 and 2014 an impairment in the amount of $110,000 and $27,080, respectively. The licenses are being amortized over an economic useful life of 15-17 years. The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at: December 31, 2015 December 31, 2014 Licenses and amortizable patents $ 97,244 $ 207,244 Unamortized patents 179,393 166,159 Accumulated amortization (44,053 ) (30,569 ) Patents and Licenses, net $ 232,584 $ 342,834 Amortization expense for licenses and amortizable patents were $13,484 and $14,442 for the years ended December 31, 2015 and 2014, respectively. Annual aggregate amortization expense for our licenses and amortizable patents for each of the next five years through December 31, 2020, is $4,396 per year and for years 2021 and later it is estimated to be $31,214.

NOTE 6 - ACCOUNTS PAYABLE AND A

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accrued expenses (included with accounts payable) consisted of the following at: December 31, 2015 December 31, 2014 Executive compensation $ 327,285 $ 153,432 Other accruals 38,022 19,725 $ 365,307 $ 173,157

NOTE 7 - NOTES PAYABLE

NOTE 7 - NOTES PAYABLE	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 7 – NOTES PAYABLE Notes payable consists of the following at: December 31, 2015 December 31, 2014 Notes payable - current 7.85% unsecured, $473 due monthly $ - $ 2,304 5.86% unsecured, $781 due monthly 2,687 - 4.15% unsecured, $3,436 due monthly 36,374 - 4.15% unsecured, $3,436 due monthly - 23,726 10.00% unsecured, interest only, due on demand. Note was settled on May 29, 2015 in exchange for 250,000 shares of common stock. In addition, 500,000 3-year warrants were granted and vested with an exercise price ranging from $0.125 - $0.15. We calculated and posted a loss on the settlement in the amount of $32,500. - 25,000 $ 39,061 $ 51,030 Convertible notes payable, net 8% secured due on December 26, 2015 (net of discount related to beneficial conversion feature of $0 in 2015 and $7,746 in 2014), convertible into preferred stock at $5.00 per share. During 2016, this note was exchanged with an effective date of December 26, 2015. Refer to Note 13 – Subsequent Events for further disclosure $ 50,000 $ 42,254 6% unsecured, convertible into common stock at $2.00 per share, due on demand 50,000 50,000 10% unsecured due December 31, 2015 (net of discount related to warrants of $0 in 2015 and $1,727 in 2014) convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share. During 2016, this note was exchanged with an effective date of December 31, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 10,000 8,273 10% unsecured due October 16, 2015 (net of discount related to warrants of $0 in 2015 and $1,805 in 2014) convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share. During 2016, this note was exchanged with an effective date of October 16, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 10,000 8,195 8% unsecured due November 25, 2018 (net of discount related to warrants of $3,019 in 2015 and $0 in 2014) convertible into common stock at $0.10 per share. 46,981 - 0% unsecured due November 3, 2015 (net of discount related to beneficial conversion feature of $0 in 2015 and $2,738 in 2014 and net of discount related to warrants of $0 in 2015 and $2,863 in 2014 and convertible into common stock at $0.30 per share.) During 2016, this note was exchanged with an effective date of November 3, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 15,000 9,399 Nine convertible notes payable (net of debt discount of $90,076) with interest between 8% to 10% were paid in cash or converted into common stock during 2015. - 239,525 $ 181,981 $ 357,646 Line of Credit

NOTE 8 - RELATED PARTY TRANSACT

NOTE 8 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 – RELATED PARTY TRANSACTIONS Debt agreements from board member Common stock issued On April 17, 2015, the board of directors authorized and granted to its executives and board or directors for the year end 2015, restricted common stock bonuses as follows: · Marvin Hausman, former CEO and director, 600,000 shares valued at $120,000 · Devin Andres, former COO, 550,000 shares valued at $110,000 · Philip Sobol, former director, 200,000 shares valued at $40,000, and · Elliott Shelton, director, 200,000 shares valued at $40,000.

NOTE 9 - STOCKHOLDERS' EQUITY (

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock On May 26, 2011, our board of directors designated 350,000 shares of preferred stock as Series A preferred stock, $0.001 par value. The Series A preferred stock is entitled to a liquidation preference in the amount of $5 per share, votes on an as converted basis with the common stock on all matters as to which holders of common stock shall be entitled to vote, and is convertible into common stock on a one-for-ten basis. Common stock The Company is authorized to issue 150,000,000 shares of common stock at $0.001 par value. Stock incentive plan The Entia Biosciences, Inc. 2010 Stock Incentive Plan was adopted by the board of directors on September 17, 2010 and approved by the stockholders on October 21, 2010. Initially 15 million shares were reserved for issuance under the Plan. On January 1, 2012, 500,000 additional shares were automatically added to the shares reserved for issuance under the Plan, pursuant to an evergreen provision in the Plan. On February 15, 2012, pursuant to a 1:10 reverse stock split the number of shares reserved for issuance under the Plan was reduced from 15,500,000 shares to 1,550,000 shares. During 2013 and 2014, an additional 100,000 shares were automatically added to the shares reserved for issuance under the Plan and the shareholders, on two separate occasions, approved an additional 1.5 million shares each to be added bringing the total shares reserved to 4,650,000 shares. On January 1, 2015, another 50,000 shares were automatically added to the shares reserved for issuance bringing the total to 4,700,000 shares. Stock options are granted at or below the closing price of our stock on the date of grant for terms ranging from four to fifteen years and generally vest over a five-year period. The fair value of the option grants was calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions: December 31, 2015 December 31, 2014 Expected dividend yield - - Expected stock price volatility 187.7% - 201.79 % 182.94% - 216.96 % Risk-free interest rate 1.47% - 1.68 % 0.28% - 1.91 % Expected term (in years) 5 years 3 - 7 years Weighted-average granted date fair value $ 0.16 $ 0.45 A summary of option activity under the stock option plan as of December 31, 2015, and changes during the year then ended is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Exercise Contractual Term Intrinsic Shares Range Price (Years) Value Outstanding, December 31, 2013 2,352,099 $ 0.38 - $1.00 $ 0.51 7.90 199,505 Exercisable, December 31, 2013 1,810,344 $ 0.38 - $1.00 $ 0.52 7.88 138,707 Granted 624,571 $ 0.40-$0.75 $ 0.52 6.49 - Exercised - - $ - - - Expired/Forfeited 110,200 $ 0.40-$0.50 $ 0.48 9.51 - Outstanding, December 31, 2014 2,866,470 $ 0.30 - $1.00 $ 0.48 8.96 - Exercisable, December 31, 2014 2,321,001 $ 0.38 - $1.00 $ 0.47 9.50 - Granted 50,000 $ 0.09 - $0.20 $ 0.16 5.00 - Exercised - - $ - - - Expired/Forfeited 18,250 $ 0.40 - $0.50 $ 0.49 8.73 - Outstanding, December 31, 2015 2,898,220 $ .0.20 - $1.00 $ 0.43 11.25 - Exercisable, December 31, 2015 2,661,493 $ 0.096 - $1.00 $ 0.42 11.66 - The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at December 31, 2015 are as follows: Number of Exercise shares Price 20,000 $ 0.09 190,000 $ 0.20 300,000 $ 0.30 55,000 $ 0.38 1,386,670 $ 0.40 10,000 $ 0.45 613,550 $ 0.50 160,000 $ 0.60 15,000 $ 0.62 100,000 $ 0.75 10,000 $ 0.81 38,000 $ 1.00 2,898,220 At December 31, 2015, the Company had 1,801,780 unissued shares available under the Plan. Also, at December 31, 2015, the Company had $105,339 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of 9 years. Warrants Outstanding warrants to purchase common stock are as follows: Date of Issue Number of Warrants Exercise Price Expiration As of December 2014 4,653,325 $ 0.36 - $10.00 09/2016 - 10/2024 January-15 70,000 $ 0.30 - $0.50 01/2020 March-15 137,500 $ 0.10 - $0.75 03/2018 - 03/2022 April-15 6,160,000 $ 0.01 - $0.15 04/2018 - 04/2027 May-15 6,160,000 $ 0.125 - $0.23 05/2018 - 05/2022 June-15 300,000 $ 0.125 - $0.15 06/2018 July-15 1,445,000 $ 0.125 - $0.15 07/2018 Total as of December 31, 2015 18,925,825 We use the Black-Scholes option-pricing model to determine the fair value of warrants on the date of grant. In determining the fair value of warrants, we employed the following key assumptions: December 31, 2015 December 31, 2014 Risk-Free interest rate 0.28% - 1.72 % 0.28% - 2.97 % Expected dividend yield 0 % 0 % Volatility 166.10% - 204.66 % 182.81% - 222.30 % Expected life 3 - 7 years 3 - 10 years At December 31, 2015 and 2014, the weighted-average Black-Scholes value of warrants granted was $0.14 and $0.39, respectively.

NOTE 10 - INCOME TAXES

NOTE 10 - INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 10 – INCOME TAXES For the years ended December 31, 2015, and 2014, we incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2015, we had approximately $4,328,688 of net operating losses. The net operating loss carryforwards, if not utilized, will begin to expire in 2026. The components of our deferred tax assets/liabilities as of December 31, are as follows: 2015 2014 Deferred tax assets: Reserves and accruals $ 168,000 $ 114,000 Net operating loss carryforwards 1,943,000 1,472,000 Total deferred tax assets: 2,111,000 1,586,000 Deferred tax liabilities: Depreciation and amortization 6,000 8,000 Net deferred tax assets before valuation allowance 2,105,000 1,578,000 Less: Valuation allowance (2,105,000 ) (1,578,000 ) Net deferred tax assets $ - $ - For financial reporting purposes, we have incurred a loss in each period since inception. Based on the available objective evidence, including our history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, we provided for a full valuation allowance against our net deferred tax assets at December 31, 2015, and 2014. A reconciliation between the amount of income tax benefit determined by applying the applicable U.S. statutory income tax rate to pre-tax loss for the years ended December 31, is as follows: 2015 2014 Federal Statutory Rate $ (768,000 ) $ (781,000 ) Nondeductible expenses 241,000 529,000 Change in allowance on deferred tax assets (527,000 ) (252,000 ) $ - $ -

NOTE 11 - COMMITMENTS AND CONTI

NOTE 11 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 – COMMITMENTS AND CONTINGENCIES Leases The Company has a lease agreement with on its headquarters facilities that expires in May 2018. The lease terms include a base monthly rental rate of $3,343 per month, increasing to $3,410 in August 2016, and then $3,478 in August 2017. The Company has analyzed the requirement to straight-line the full value of the lease agreement over the life of the lease and has determined that there is no need to book a deferred rent liability as the amount is immaterial. Future minimum lease payments for all of our facilities amount to $57,422 for 2016, $58,298 for 2017 and $37,974 through August 2018. Rent expense for the years ended December 31, 2015 and 2014 was $55,464 and $47,988, respectively. Employment Agreements During 2015, the Company entered into employment agreements with its CEO, COO/CFO and CSO. Commencement of payment of the base salaries under these employment agreements was, and continues to be, conditional on fundraising results. Management determined that no base salary for the CEO or CSO would be accrued or paid for 2015, based primarily upon the financial needs of the Company through the end of that year. Payment of base salary commenced for the COO/CFO in December 2015. Litigation At December 31, 2015, we were and continue to be a party to litigation with respect to a note payable, with a face amount of $50,000 and the accrued interest thereon. Additionally, we are involved in arbitration with a former employee who has made claims against us, along with other potential allegations seeking approximately $93,000, plus punitive damages. In both cases, the Company will defend itself vigorously and reserves the right to make counter claims against the adversarial parties. Although we believe that these situations will be settled in due time, without material effect to the Company or its future operations, we can offer no assurance to that effect.

NOTE 12 - CONCENTRATIONS AND CR

NOTE 12 - CONCENTRATIONS AND CREDIT RISK	12 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 12 – CONCENTRATIONS AND CREDIT RISK Customers and Credit Concentrations During 2015 and 2014, approximately 42% and 47%, respectively, of our sales were to 5 customers. Accounts receivable for these customers accounted for 57% and 81% of total accounts receivable at December 31, 2015 and 2014, respectively. Vendor Concentrations During 2015, approximately 64% of our purchases were made from 5 vendors as compared to 46% during 2014. Accounts payable for these vendors accounted for 0.5% and 4% of total accounts payable at December 31, 2015 and 2014, respectively.

NOTE 13 - SUBSEQUENT EVENTS

NOTE 13 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 – SUBSEQUENT EVENTS During first quarter 2016, one investor exchanged his existing $50,000 note plus accrued interest of $9,500 into a new convertible note with a face value of $55,000. The note accrues interest at 8% per annum and is due on December 26, 2016. The note is convertible into shares of our common stock at a rate of $0.10 per share. Terms of issuance were not finalized until 2016 with an effective date of December 26, 2015. As consideration for exchanging the note, we issued the investor a three-year warrant to purchase 50,000 shares of common stock at $0.125 per share. We calculated a gain on exchange of the note in the amount of $4,500. We also calculated discount on the fair value of the warrants in the amount of $3,135 and will amortize this amount over the life of the loan. In addition, the investor exchanged two additional existing five-year warrants to purchase 50,000 shares each at $2 and $0.50, respectively for one three-year warrant to purchase 100,000 shares of common stock at $0.125 per share. We have also calculated the possible gain or loss on modification of these warrants and determined this amount to be immaterial to our financial statements. During first quarter of 2016, one investor converted his existing $10,000 note plus accrued interest of $1,133 into a three-year, 8% convertible debenture with a face value of $11,333, and convertible into shares of common stock at a rate of $0.10 per share. Terms of issuance were not finalized until 2016 with an effective date of December 31, 2015. Attached to the debenture is a three-year warrant to purchase 11,333 shares of common stock at $0.125 per share. We calculated a discount on the fair value of the warrant in the amount of $714 and will amortize it over the life of the debenture. During first quarter of 2016, one investor converted his existing $15,000 note into a three-year, 8% convertible debenture with a face value of $15,000, and convertible into shares of common stock at a rate of $0.10 per share. Terms of issuance were not finalized until 2016 with an effective date of November 3, 2015. Attached to the debenture is a three-year warrant to purchase 15,000 shares of common stock at $0.125 per share. We calculated a discount on the fair value of the warrant in the amount of $945 and will amortize it over the life of the debenture During first quarter of 2016, one investor converted his existing $10,000 note plus accrued interest of $1,208 into a new convertible three-year, 8% convertible debenture with a face value of $11,000, and convertible into shares of common stock at a rate of $0.10 per share. Terms of issuance were not finalized until 2016 with an effective date of October 16, 2015. Attached to the debenture is a three-year warrant to purchase 11,000 shares of our common stock at $0.125 per share. We calculated a discount on the fair value of the warrant in the amount of $945 and will amortize it over the life of the loan. We also calculated a gain on the exchange of the note in the amount of $208. During February 2016, we borrowed $20,000 by means of two one-year promissory notes in the amount of $10,000 each that accrue interest at the rate of 10% per annum. One of these $10,000 notes is with a related party. During February 2016, an investor exchanged 2,744 shares of Series A preferred stock for 27,440 shares of common stock. During March 2016, we issued two three-year, 8% convertible debentures in the amount of $50,000 and $25,000. The debentures are convertible into shares of common stock at the rate of $0.10 per share. Attached to each debenture is a three-year warrant to purchase 50,000 and 25,000 shares of our common stock at $0.125 per share. We calculated a discount on the fair value of the warrants in the amounts of $3,150 and $1,575, respectively, and will amortize these discounts over the life of the debentures. During April 2016, we issued a three-year, 8% convertible debenture in the amount of $100,000 and convertible into shares of common stock at the rate of $0.10 per share. Attached to the debenture is a three-year warrant to purchase 100,000 shares of our common stock at $0.125 per share. We calculated a discount on the fair value of the warrant in the amount of $6,300 and will amortize this over the life of the debenture.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation and principles of consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of Entia and Total Nutraceutical Solutions, a wholly-owned subsidiary, as of December 31, 2015 and 2014.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.
Receivables, Policy [Policy Text Block]	Accounts receivable Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable. Outstanding account balances are reviewed individually for collectibility. We determine the allowance based on historical write-off experience, customer specific facts and economic conditions. Bad debt expense is included in general and administrative expenses, if any. We generally consider accounts greater than 30 days old to be past due. Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $5,736 and $30,022 at December 31, 2015 and 2014, respectively.
Inventory, Policy [Policy Text Block]	Inventory Inventory consists of finished goods and raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the average cost method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory. The portion of inventory that is not expected to be used in production of our products for more than 12 months is a long-term asset.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs. Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Licenses Licenses that allow us to use certain technology in the production of our products are amortized on a straight-line basis over their remaining useful life (typically 15-17 years). Long-lived assets, including licenses, property and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. We have recorded an impairment on our licenses in the amount of $110,000 and $27,080 on December 31, 2015 and 2014, respectively.
Debt, Policy [Policy Text Block]	Discount on convertible notes payable We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument. The amortization is recorded as interest expense on the consolidated statement of operations.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable approximate their fair values determined based on level 1 inputs in the fair value hierarchy because of the short maturity of these instruments. Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes.
Fair Value Measurement, Policy [Policy Text Block]	Fair value measurements We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions. We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at December 31, 2015 or 2014, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the years ended December 31, 2015 and 2014.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured. Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers and distributors. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive. Allowances for product returns, primarily in connection with one distribution agreement, are provided at the time the sale is recorded. This allowance is based upon historical return rates for the Company and relevant industry patterns, which reflects anticipated returns of unopened product in its original packaging to be received over a period of 120 days following the original sale.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and handling costs Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred. In 2015 and 2014, we incurred $27,848 and $34,286, respectively, in shipping costs included in cost of goods sold.
Advertising Costs, Policy [Policy Text Block]	Advertising costs Costs associated with the advertising of our products are expensed as incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs are charged to expense as incurred. Research and development costs consist primarily of material and testing costs for research and development as well as research and development arrangements with unrelated third party research and development institutions. These research and development arrangements usually involve one specific research and development project. We may make non-refundable advances upon signing of these arrangements. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or as the related services are performed. Management periodically evaluates whether the goods will be delivered or services will be rendered. If management does not expect the goods to be delivered or services to be rendered, the capitalized advance payment is charged to expense. Research and development expense was $ 73,394
Stockholders' Equity, Policy [Policy Text Block]	Equity instruments issued to parties other than employees for acquiring goods or services We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. Currently such transactions are primarily awards of warrants to purchase common stock. The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The assumptions used to determine the fair value of our warrants are as follows: - The expected life of warrants issued represents the period of time the warrants are expected to be outstanding. - The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant. - The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant. - The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant. During 2015 and 2014, we issued restricted common stock, warrants and non-statutory stock options to attorneys, scientific, marketing and financial consultants and our external contract accountants. The value of these instruments equal $384,922 of the total $589,616 for 2015 and $257,689 of the total $642,897 for 2014.
Income Tax, Policy [Policy Text Block]	Income taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. The tax years that are open to examination are 2012, 2013, 2014 and 2015.
Earnings Per Share, Policy [Policy Text Block]	Net loss per common share Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2015 and 2014. The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2015 2014 Numerator: Net loss allocable to common stockholders $ (2,260,050 ) $ (2,296,591 ) Denominator: Weighted-average common shares outstanding 24,289,381 9,442,352 Basic and diluted net loss per share $ (0.09 ) $ (0.24 ) Common stock warrants 18,925,825 7,110,701 Series A convertible preferred stock 1,913,070 2,008,070 Stock options 2,898,220 2,866,470 Convertible debt including interest 601,775 1,317,604 Excluded dilutive securities 24,338,890 13,302,845
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation.
Segment Reporting, Policy [Policy Text Block]	Segments We have determined that we operate in one segment for financial reporting purposes.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently issued accounting pronouncements In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia in the first quarter of 2018, and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.

NOTE 2 - SUMMARY OF SIGNIFICA22

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2015 2014 Numerator: Net loss allocable to common stockholders $ (2,260,050 ) $ (2,296,591 ) Denominator: Weighted-average common shares outstanding 24,289,381 9,442,352 Basic and diluted net loss per share $ (0.09 ) $ (0.24 ) Common stock warrants 18,925,825 7,110,701 Series A convertible preferred stock 1,913,070 2,008,070 Stock options 2,898,220 2,866,470 Convertible debt including interest 601,775 1,317,604 Excluded dilutive securities 24,338,890 13,302,845
Estimated Useful Lives [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement

NOTE 3 - INVENTORY (Tables)

NOTE 3 - INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following at: December 31, 2015 December 31, 2014 Raw materials $ 27,313 $ 202,591 Finished goods 219,074 43,849 246,387 246,440 Less reserve for excess and obsolete inventory (151,064 ) (151,064 ) 95,323 95,376 Less current portion (40,323 ) (48,043 ) $ 55,000 $ 47,333

NOTE 4 - PROPERTY AND EQUIPME24

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment Table [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, consists of the following at: December 31, 2015 December 31, 2014 Office equipment $ 31,658 $ 27,507 Production equipment 90,899 86,999 Leasehold improvements 16,328 16,328 138,885 130,834 Less: accumulated depreciation (106,199 ) (87,687 ) $ 32,686 $ 43,147

NOTE 5 - PATENTS AND LICENSES25

NOTE 5 - PATENTS AND LICENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at: December 31, 2015 December 31, 2014 Licenses and amortizable patents $ 97,244 $ 207,244 Unamortized patents 179,393 166,159 Accumulated amortization (44,053 ) (30,569 ) Patents and Licenses, net $ 232,584 $ 342,834

NOTE 6 - ACCOUNTS PAYABLE AND26

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses (included with accounts payable) consisted of the following at: December 31, 2015 December 31, 2014 Executive compensation $ 327,285 $ 153,432 Other accruals 38,022 19,725 $ 365,307 $ 173,157

NOTE 7 - NOTES PAYABLE (Tables)

NOTE 7 - NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes payable consists of the following at: December 31, 2015 December 31, 2014 Notes payable - current 7.85% unsecured, $473 due monthly $ - $ 2,304 5.86% unsecured, $781 due monthly 2,687 - 4.15% unsecured, $3,436 due monthly 36,374 - 4.15% unsecured, $3,436 due monthly - 23,726 10.00% unsecured, interest only, due on demand. Note was settled on May 29, 2015 in exchange for 250,000 shares of common stock. In addition, 500,000 3-year warrants were granted and vested with an exercise price ranging from $0.125 - $0.15. We calculated and posted a loss on the settlement in the amount of $32,500. - 25,000 $ 39,061 $ 51,030
Convertible Debt [Table Text Block]	Convertible notes payable, net 8% secured due on December 26, 2015 (net of discount related to beneficial conversion feature of $0 in 2015 and $7,746 in 2014), convertible into preferred stock at $5.00 per share. During 2016, this note was exchanged with an effective date of December 26, 2015. Refer to Note 13 – Subsequent Events for further disclosure $ 50,000 $ 42,254 6% unsecured, convertible into common stock at $2.00 per share, due on demand 50,000 50,000 10% unsecured due December 31, 2015 (net of discount related to warrants of $0 in 2015 and $1,727 in 2014) convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share. During 2016, this note was exchanged with an effective date of December 31, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 10,000 8,273 10% unsecured due October 16, 2015 (net of discount related to warrants of $0 in 2015 and $1,805 in 2014) convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share. During 2016, this note was exchanged with an effective date of October 16, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 10,000 8,195 8% unsecured due November 25, 2018 (net of discount related to warrants of $3,019 in 2015 and $0 in 2014) convertible into common stock at $0.10 per share. 46,981 - 0% unsecured due November 3, 2015 (net of discount related to beneficial conversion feature of $0 in 2015 and $2,738 in 2014 and net of discount related to warrants of $0 in 2015 and $2,863 in 2014 and convertible into common stock at $0.30 per share.) During 2016, this note was exchanged with an effective date of November 3, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 15,000 9,399 Nine convertible notes payable (net of debt discount of $90,076) with interest between 8% to 10% were paid in cash or converted into common stock during 2015. - 239,525 $ 181,981 $ 357,646

NOTE 9 - STOCKHOLDERS' EQUITY28

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the option grants was calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions: December 31, 2015 December 31, 2014 Expected dividend yield - - Expected stock price volatility 187.7% - 201.79 % 182.94% - 216.96 % Risk-free interest rate 1.47% - 1.68 % 0.28% - 1.91 % Expected term (in years) 5 years 3 - 7 years Weighted-average granted date fair value $ 0.16 $ 0.45
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of option activity under the stock option plan as of December 31, 2015, and changes during the year then ended is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Exercise Contractual Term Intrinsic Shares Range Price (Years) Value Outstanding, December 31, 2013 2,352,099 $ 0.38 - $1.00 $ 0.51 7.90 199,505 Exercisable, December 31, 2013 1,810,344 $ 0.38 - $1.00 $ 0.52 7.88 138,707 Granted 624,571 $ 0.40-$0.75 $ 0.52 6.49 - Exercised - - $ - - - Expired/Forfeited 110,200 $ 0.40-$0.50 $ 0.48 9.51 - Outstanding, December 31, 2014 2,866,470 $ 0.30 - $1.00 $ 0.48 8.96 - Exercisable, December 31, 2014 2,321,001 $ 0.38 - $1.00 $ 0.47 9.50 - Granted 50,000 $ 0.09 - $0.20 $ 0.16 5.00 - Exercised - - $ - - - Expired/Forfeited 18,250 $ 0.40 - $0.50 $ 0.49 8.73 - Outstanding, December 31, 2015 2,898,220 $ .0.20 - $1.00 $ 0.43 11.25 - Exercisable, December 31, 2015 2,661,493 $ 0.096 - $1.00 $ 0.42 11.66 -
Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Table Text Block]	The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at December 31, 2015 are as follows: Number of Exercise shares Price 20,000 $ 0.09 190,000 $ 0.20 300,000 $ 0.30 55,000 $ 0.38 1,386,670 $ 0.40 10,000 $ 0.45 613,550 $ 0.50 160,000 $ 0.60 15,000 $ 0.62 100,000 $ 0.75 10,000 $ 0.81 38,000 $ 1.00 2,898,220
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding warrants to purchase common stock are as follows: Date of Issue Number of Warrants Exercise Price Expiration As of December 2014 4,653,325 $ 0.36 - $10.00 09/2016 - 10/2024 January-15 70,000 $ 0.30 - $0.50 01/2020 March-15 137,500 $ 0.10 - $0.75 03/2018 - 03/2022 April-15 6,160,000 $ 0.01 - $0.15 04/2018 - 04/2027 May-15 6,160,000 $ 0.125 - $0.23 05/2018 - 05/2022 June-15 300,000 $ 0.125 - $0.15 06/2018 July-15 1,445,000 $ 0.125 - $0.15 07/2018 Total as of December 31, 2015 18,925,825
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	In determining the fair value of warrants, we employed the following key assumptions: December 31, 2015 December 31, 2014 Risk-Free interest rate 0.28% - 1.72 % 0.28% - 2.97 % Expected dividend yield 0 % 0 % Volatility 166.10% - 204.66 % 182.81% - 222.30 % Expected life 3 - 7 years 3 - 10 years

NOTE 10 - INCOME TAXES (Tables)

NOTE 10 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The components of our deferred tax assets/liabilities as of December 31, are as follows: 2015 2014 Deferred tax assets: Reserves and accruals $ 168,000 $ 114,000 Net operating loss carryforwards 1,943,000 1,472,000 Total deferred tax assets: 2,111,000 1,586,000 Deferred tax liabilities: Depreciation and amortization 6,000 8,000 Net deferred tax assets before valuation allowance 2,105,000 1,578,000 Less: Valuation allowance (2,105,000 ) (1,578,000 ) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation between the amount of income tax benefit determined by applying the applicable U.S. statutory income tax rate to pre-tax loss for the years ended December 31, is as follows: 2015 2014 Federal Statutory Rate $ (768,000 ) $ (781,000 ) Nondeductible expenses 241,000 529,000 Change in allowance on deferred tax assets (527,000 ) (252,000 ) $ - $ -

NOTE 1 - ORGANIZATION AND OPE30

NOTE 1 - ORGANIZATION AND OPERATIONS (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure Text Block [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 24,133	$ 99,462	$ 36,886

NOTE 2 - SUMMARY OF SIGNIFICA31

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Allowance for Doubtful Accounts Receivable	$ 5,736	$ 30,022
Impairment of Intangible Assets, Finite-lived	110,000	27,080
Shipping, Handling and Transportation Costs	27,848	34,286
Research and Development Expense	73,394	24,523
Share-based Compensation	$ 589,616	642,897
Number of Operating Segments	1
Equity Issued for Services [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Stock Issued During Period, Value, Issued for Services	$ 384,922	$ 257,689
Domestic Patents [Member] | Minimum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Domestic Patents [Member] | Maximum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Foreign Patents [Member] | Minimum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Foreign Patents [Member] | Maximum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Technology-Based Intangible Assets [Member] | Minimum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Technology-Based Intangible Assets [Member] | Maximum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	17 years

NOTE 2 - SUMMARY OF SIGNIFICA32

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Property, Plant and Equipment, Estimated Useful Lives	12 Months Ended
	Dec. 31, 2015
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	Lesser of lease term or useful life of improvement
Minimum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years

NOTE 2 - SUMMARY OF SIGNIFICA33

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Numerator:
Net loss allocable to common stockholders (in Dollars)	$ (2,260,050)	$ (2,296,591)
Denominator:
Weighted-average common shares outstanding	24,289,381	9,442,352
Basic and diluted net loss per share (in Dollars per share)	$ (0.09)	$ (0.24)
Excluded dilutive securties	24,338,890	13,302,845
Warrant [Member]
Denominator:
Excluded dilutive securties	18,925,825	7,110,701
Convertble Preferred Shares [Member]
Denominator:
Excluded dilutive securties	1,913,070	2,008,070
Equity Option [Member]
Denominator:
Excluded dilutive securties	2,898,220	2,866,470
Convertible Debt Securities [Member]
Denominator:
Excluded dilutive securties	601,775	1,317,604

NOTE 3 - INVENTORY (Details) -

NOTE 3 - INVENTORY (Details) - Schedule of Inventory - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule of Inventory [Abstract]
Raw materials	$ 27,313	$ 202,591
Finished goods	219,074	43,849
	246,387	246,440
Less reserve for excess and obsolete inventory	(151,064)	(151,064)
	95,323	95,376
Less current portion	(40,323)	(48,043)
	$ 55,000	$ 47,333

NOTE 4 - PROPERTY AND EQUIPME35

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation	$ 18,512	$ 23,605

NOTE 4 - PROPERTY AND EQUIPME36

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 138,885	$ 130,834
Less: accumulated depreciation	(106,199)	(87,687)
	32,686	43,147
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	31,658	27,507
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	90,899	86,999
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 16,328	$ 16,328

NOTE 5 - PATENTS AND LICENSES37

NOTE 5 - PATENTS AND LICENSES, NET (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 110,000	$ 27,080
Licensing Agreements [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Amortization of Intangible Assets	13,484	$ 14,442
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	4,396
Finite-Lived Intangible Assets, Amortization Expense, Year Two	4,396
Finite-Lived Intangible Assets, Amortization Expense, Year Three	4,396
Finite-Lived Intangible Assets, Amortization Expense, Year Four	4,396
Finite-Lived Intangible Assets, Amortization Expense, Year Five	4,396
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	$ 31,214
Licensing Agreements [Member] | Minimum [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Licensing Agreements [Member] | Maximum [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	17 years

NOTE 5 - PATENTS AND LICENSES38

NOTE 5 - PATENTS AND LICENSES, NET (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ (44,053)	$ (30,569)
Patents and Licenses, net	232,584	342,834
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangilble assets, gross	97,244	207,244
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangilble assets, gross	$ 179,393	$ 166,159

NOTE 6 - ACCOUNTS PAYABLE AND39

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule of Accrued Liabilities [Abstract]
Executive compensation	$ 327,285	$ 153,432
Other accruals	38,022	19,725
	$ 365,307	$ 173,157

NOTE 7 - NOTES PAYABLE (Details

NOTE 7 - NOTES PAYABLE (Details) - USD ($)	Mar. 25, 2014	Dec. 31, 2015	Dec. 31, 2014
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Line of Credit, Current		$ 58,195	$ 16,179
Line of Credit [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 60,000
Line of Credit Facility, Interest Rate at Period End		6.50%
Prime Rate [Member] | Line of Credit [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.00%

NOTE 7 - NOTES PAYABLE (Detai41

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Notes payable - current
Notes payable	$ 39,061	$ 51,030
Note Payable 1 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable	0	2,304
Note Payable 2 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable	2,687	0
Note Payable 3 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable	36,374	0
Note Payable 4 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable	0	23,726
Note Payable 5 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable	$ 0	$ 25,000

NOTE 7 - NOTES PAYABLE (Detai42

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Warrants granted		4,653,325
Note, loss on settlement	$ 32,500	$ 169,187
Note Payable 1 [Member] | Loans Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%		7.85%
Due monthly		$ 473
Note Payable 2 [Member] | Loans Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%	5.86%
Due monthly	$ 781
Note Payable 3 [Member] | Loans Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%	4.15%
Due monthly	$ 3,436
Note Payable 4 [Member] | Loans Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%		4.15%
Due monthly		$ 3,436
Note Payable 5 [Member] | Loans Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%		10.00%
Due		Due on demand
Note settled in exchange for common stock		250,000
Warrants granted		500,000
Note, loss on settlement		$ 32,500
Warrants		3 years
Minimum [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Warrants, exercise price		$ 0.36
Minimum [Member] | Note Payable 5 [Member] | Loans Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Warrants, exercise price		0.125
Maximum [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Warrants, exercise price		10
Maximum [Member] | Note Payable 5 [Member] | Loans Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Warrants, exercise price		$ 0.15

NOTE 7 - NOTES PAYABLE (Detai43

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt - USD ($)	Dec. 31, 2015	Dec. 31, 2014
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	$ 181,981	$ 357,646
Convertible Note 1 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	50,000	42,254
Convertible Note 2 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	50,000	50,000
Convertible Note 3 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	10,000	8,273
Convertible Note 4 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	10,000	8,195
Convertible Note 5 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	46,981	0
Convertible Note 6 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	15,000	9,399
Nine Covertible Notes Payable [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	$ 0	$ 239,525

NOTE 7 - NOTES PAYABLE (Detai44

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) - Convertible Notes Payable [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Convertible Note 1 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%	8.00%
Due	Dec. 26, 2015	Dec. 26, 2015
Discount related to beneficial conversion feature	$ 0	$ 7,746
Convertible at	$ 5	$ 5
Convertible Note 2 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	6.00%	6.00%
Convertible at	$ 2	$ 2
Due	Due on demand	Due on demand
Convertible Note 3 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%	10.00%
Due	December 2,015	December 2,015
Discount related to warrants	$ 0	$ 1,727
Convertible price	convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share	convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share
Convertible Note 4 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%	10.00%
Due	October 2,015	October 2,015
Discount related to warrants	$ 0	$ 1,805
Convertible price	convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share	convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share
Convertible Note 5 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%
Due	Nov. 25, 2018
Convertible at	$ 0.10
Discount related to warrants	$ 0
Convertible Note 6 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	0.00%	0.00%
Discount related to beneficial conversion feature	$ 0	$ 2,738
Convertible at	$ 0.30	$ 0.30
Due	November 2,015	November 2,015
Discount related to warrants	$ 0	$ 2,863
Nine Covertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
Discount related to beneficial conversion feature		$ 90,076
Minimum [Member] | Nine Covertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%		8.00%
Maximum [Member] | Nine Covertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%		10.00%

NOTE 8 - RELATED PARTY TRANSA45

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Apr. 17, 2015	Jul. 01, 2014	Sep. 30, 2014	Dec. 31, 2014
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)				4,653,325
Director [Member] | Convertible Debt [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		0.00%
Debt Instrument, Face Amount		$ 15,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 0.50
Warrants, Fair Value of Warrants, Granted		$ 5,445
Debt Instrument, Convertible, Conversion Price (in Dollars per share)		$ 0.50
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 7,545
Director [Member] | Note Extension [Member] | Convertible Debt [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 0.20
Warrants, Fair Value of Warrants, Granted			$ 3,435
Debt Instrument, Convertible, Conversion Price (in Dollars per share)			$ 0.30
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 3,285
Class of Warrant or Rights, Granted (in Shares)			15,000
Director [Member] | Issuance to Director #1 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	200,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 40,000
Director [Member] | Issucance to Director #2 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	200,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 40,000
Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	600,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 120,000
Chief Operating Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	550,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 110,000

NOTE 9 - STOCKHOLDERS' EQUITY46

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - USD ($)	Jan. 01, 2015	Jan. 01, 2012	May. 26, 2011	Sep. 17, 2010	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Feb. 15, 2012
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Preferred Stock, Shares Authorized					5,000,000	5,000,000
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)			$ 5
Warrants, Grants in Period, Weighted-Average Grant Date Fair Value (in Dollars per share)					$ 0.14	$ 0.39
2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	4,700,000			15,000,000		4,650,000		1,550,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	50,000	500,000				1,500,000	1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					1,801,780
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)					$ 105,339
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					9 years
2010 Stock Incentive Plan [Member] | Automatic Increase in Shares Authorized [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized						100,000	100,000
Stock Issued for Services Rendered [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross					150,000,000
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)					$ 0.001
Series A Preferred Stock [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Preferred Stock, Shares Authorized			350,000		350,000	350,000
Preferred Stock, No Par Value (in Dollars per share)			$ 0.001
Preferred Stock, Conversion Basis			one-for-ten
Minimum [Member] | 2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				4 years
Maximum [Member] | 2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				15 years

NOTE 9 - STOCKHOLDERS' EQUITY47

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Stock Options, Valuation Assumptions - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Stock Options, Valuation Assumptions [Line Items]
Expected dividend yield	0.00%	0.00%
Expected term (in years)	5 years
Weighted-average granted date fair value (in Dollars per share)	$ 0.16	$ 0.45
Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Stock Options, Valuation Assumptions [Line Items]
Expected stock price volatility	187.70%	182.94%
Risk-free interest rate	1.47%	0.28%
Expected term (in years)		3 years
Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Stock Options, Valuation Assumptions [Line Items]
Expected stock price volatility	201.79%	216.96%
Risk-free interest rate	1.68%	1.91%
Expected term (in years)		7 years

NOTE 9 - STOCKHOLDERS' EQUITY48

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Number of Shares (in Shares)	2,866,470		2,352,099
Options Outstanding, Weighted Average Exercise Price	$ 0.48		$ 0.51
Options Outstanding, Weighted Average Remaining Contractual Term	11 years 3 months	8 years 350 days	7 years 328 days
Options Outstanding, Average Intrinsic Value (in Dollars)			$ 199,505,000,000
Options Exercisable, Number of Shares (in Shares)	2,321,001		1,810,344
Options Exercisable, Weighted Average Exercise Price	$ 0.47		$ 0.52
Options Exercisable, Weighted Average Remaining Contractual Term	11 years 240 days	9 years 6 months	7 years 321 days
Options Exercisable, Average Intrinsic Value (in Dollars)			$ 138,707,000,000
Options Granted, Number of Shares (in Shares)	50,000	624,571
Options Granted, Weighted Average Exercise Price	$ 0.16	$ 0.52
Options Granted, Weighted Average Remaining Contractual Term	5 years	6 years 178 days
Options Exercised, Number of Shares (in Shares)	0	0
Options Exercised, Weighted Average Exercise Price	$ 0	$ 0
Options Exercisted, Average Intrinsic Value (in Dollars)	$ 0	$ 0
Options Expired, Number of Shares (in Shares)	18,250	110,200
Options Expired, Weighted Average Exercise Price	$ 0.49	$ 0.48
Options Expired, Weighted Average Remaining Contractual Term	8 years 266 days	9 years 186 days
Options Outstanding, Number of Shares (in Shares)	2,898,220	2,866,470
Options Outstanding, Weighted Average Exercise Price	$ 0.43	$ 0.48
Options Exercisable, Number of Shares (in Shares)	2,661,493	2,321,001
Options Exercisable, Weighted Average Exercise Price	$ 0.42	$ 0.47
Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Exercise Price	0.30		$ 0.38
Options Exercisable, Exercise Price	0.38		0.38
Options Granted, Exercise Price	0.09	0.40
Options Expired, Exercise Price	0.40	0.40
Options Outstanding, Exercise Price	0.20	0.30
Options Exercisable, Exercise Price	0.096	0.38
Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Exercise Price	1		1
Options Exercisable, Exercise Price	1		$ 1
Options Granted, Exercise Price	0.20	0.75
Options Expired, Exercise Price	0.50	0.50
Options Outstanding, Exercise Price	1	1
Options Exercisable, Exercise Price	$ 1	$ 1

NOTE 9 - STOCKHOLDERS' EQUITY49

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2012
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	2,898,220	2,866,470	2,352,099
Options Exerciable at $0.09 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	20,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.09
Options Exercisable at $0.20 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	190,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.20
Options Exercisable at $0.30 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	300,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.30
Options Exercisable at $0.38 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	55,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.38
Options Exercisable at $0.40 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	1,386,670
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.40
Options Exercisable at $0.45 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	10,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.45
Options Exercisable at $0.50 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	613,550
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.50
Options Exercisable at $0.60 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	160,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.60
Options Exercisable at $0.62 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	15,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.62
Options Exercisable at $0.75 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	100,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.75
Options Exercisable at $0.81 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	10,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.81
Options Exercisable at $1.00 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	38,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 1

NOTE 9 - STOCKHOLDERS' EQUITY50

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Stockholders' Equity Note, Warrants - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Warrants Outstanding (in Shares)		4,653,325
Warrants Expiration		09/2016 - 10/2024
Warrants Issued January 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in Shares)	70,000
Warrants Expiration	01/2020
Warrants Issued March 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in Shares)	137,500
Warrants Expiration	03/2018 - 03/2022
Warrants Issued April 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in Shares)	6,160,000
Warrants Expiration	04/2018 - 04/2027
Warrants Issued May 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in Shares)	6,160,000
Warrants Expiration	05/2018 - 05/2022
Warrants Issued June 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in Shares)	300,000
Warrants Expiration	06/2018
Warrants Issued July 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in Shares)	1,445,000
Warrants Expiration	07/2018
Total as of December 31, 2015 (in Shares)	18,925,825
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price		$ 0.36
Minimum [Member] | Warrants Issued January 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	$ 0.30
Minimum [Member] | Warrants Issued March 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.10
Minimum [Member] | Warrants Issued April 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.01
Minimum [Member] | Warrants Issued May 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.125
Minimum [Member] | Warrants Issued June 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.125
Minimum [Member] | Warrants Issued July 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.125
Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price		$ 10
Maximum [Member] | Warrants Issued January 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.50
Maximum [Member] | Warrants Issued March 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.75
Maximum [Member] | Warrants Issued April 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.15
Maximum [Member] | Warrants Issued May 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.23
Maximum [Member] | Warrants Issued June 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	0.15
Maximum [Member] | Warrants Issued July 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price	$ 0.15

NOTE 9 - STOCKHOLDERS' EQUITY51

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Warrants, Valuation Assumptions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-Free interest rate	0.28%	0.28%
Volatility	166.10%	182.81%
Expected life	3 years	3 years
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-Free interest rate	1.72%	2.97%
Volatility	204.66%	222.30%
Expected life	7 years	10 years

NOTE 10 - INCOME TAXES (Details

NOTE 10 - INCOME TAXES (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 4,328,688
Operating Loss Carryforwards, Expiration Date	2,026

NOTE 10 - INCOME TAXES (Detai53

NOTE 10 - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Reserves and accruals	$ 168,000	$ 114,000
Net operating loss carryforwards	1,943,000	1,472,000
Total deferred tax assets:	2,111,000	1,586,000
Deferred tax liabilities:
Depreciation and amortization	6,000	8,000
Net deferred tax assets before valuation allowance	2,105,000	1,578,000
Less: Valuation allowance	(2,105,000)	(1,578,000)
Net deferred tax assets	$ 0	$ 0

NOTE 10 - INCOME TAXES (Detai54

NOTE 10 - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Federal Statutory Rate	$ (768,000)	$ (781,000)
Nondeductible expenses	241,000	529,000
Change in allowance on deferred tax assets	(527,000)	(252,000)
	$ 0	$ 0

NOTE 11 - COMMITMENTS AND CON55

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 57,422
Operating Leases, Future Minimum Payments, Due in Two Years	58,298
Operating Leases, Future Minimum Payments, Due in Three Years	37,974
Operating Leases, Rent Expense, Net	55,464	$ 47,988
Litigation, Note Payable [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Debt Instrument, Face Amount	50,000
Litigation, Former Employee [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought, Value	93,000
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 1 [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	3,343
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 2 [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	3,410
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 3 [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	$ 3,478

NOTE 12 - CONCENTRATIONS AND 56

NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Five Vendors [Member] | Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	64.00%	46.00%
Five Vendors [Member] | Liabilities, Total [Member] | Supplier Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	0.50%	4.00%
Five Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	42.00%	47.00%
Five Customers [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	57.00%	81.00%

NOTE 13 - SUBSEQUENT EVENTS (De

NOTE 13 - SUBSEQUENT EVENTS (Details)	1 Months Ended			3 Months Ended	12 Months Ended
	Apr. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Feb. 29, 2016shares	Mar. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Feb. 16, 2016USD ($)
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares) | shares						4,653,325
Gains (Losses) on Restructuring of Debt					$ 6,906	$ 103,021
Subsequent Event [Member] | Series A Preferred Stock [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Converted (in Shares) | shares			2,744
Conversion of Stock, Shares Issued (in Shares) | shares			27,440
Convertible Notes Payable [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount	$ 100,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 0.10
Warrants, Term of Warrants	3 years
Class of Warrant or Rights, Granted (in Shares) | shares	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares	$ 0.125
Warrants, Fair Value of Warrants, Granted	$ 6,300
Debt Instrument, Term	3 years
Two Warrants Exchanged for One Warrant [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Warrants, Term of Warrants				3 years
Class of Warrant or Rights, Granted (in Shares) | shares				100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.125		$ 0.125
Warrant Exercisable at $2.00 [Member] | Two Warrants Exchanged for One Warrant [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Warrants, Term of Warrants					5 years
Class of Warrant or Rights, Granted (in Shares) | shares					50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares					$ 2
Warrant Exercisable at $0.50 [Member] | Two Warrants Exchanged for One Warrant [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Warrants, Term of Warrants					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares					$ 0.50
Restructure of Note Payable to Convertible Note Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Number of Investors					1
Debt Instrument, Face Amount					$ 50,000
Interest Payable					$ 9,500
Restructure of Note Payable to Convertible Note Payable [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount		$ 55,000		$ 55,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%
Debt Instrument, Maturity Date				Dec. 26, 2016
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.10		$ 0.10
Warrants, Term of Warrants				3 years
Class of Warrant or Rights, Granted (in Shares) | shares				50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.125		$ 0.125
Gains (Losses) on Restructuring of Debt				$ 4,500
Warrants, Fair Value of Warrants, Granted				3,135
Restructure of Note Payable to Convertible Note Payable #2 [Member] | Notes Payable, Other Payables [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Number of Investors					1
Debt Instrument, Face Amount					$ 10,000
Interest Payable					$ 1,133
Restructure of Note Payable to Convertible Note Payable #2 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount		$ 11,333		$ 11,333
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.10		$ 0.10
Warrants, Term of Warrants				3 years
Class of Warrant or Rights, Granted (in Shares) | shares				11,333
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.125		$ 0.125
Warrants, Fair Value of Warrants, Granted				$ 714
Debt Instrument, Term				3 years
Restructure of Note Payable to Convertible Note Payable #3 [Member] | Notes Payable, Other Payables [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Number of Investors					1
Debt Instrument, Face Amount					$ 15,000
Restructure of Note Payable to Convertible Note Payable #3 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount		$ 15,000		$ 15,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.10		$ 0.10
Warrants, Term of Warrants				3 years
Class of Warrant or Rights, Granted (in Shares) | shares				15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.125		$ 0.125
Warrants, Fair Value of Warrants, Granted				$ 945
Debt Instrument, Term				3 years
Restructure of Note Payable to Convertible Note Payable #4 [Member] | Notes Payable, Other Payables [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Number of Investors					1
Debt Instrument, Face Amount					$ 10,000
Interest Payable					$ 1,208
Restructure of Note Payable to Convertible Note Payable #4 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount		$ 11,000		$ 11,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.10		$ 0.10
Warrants, Term of Warrants				3 years
Class of Warrant or Rights, Granted (in Shares) | shares				11,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.125		$ 0.125
Gains (Losses) on Restructuring of Debt				$ 208
Warrants, Fair Value of Warrants, Granted				$ 945
Debt Instrument, Term				3 years
Note Payable 2 [Member] | Notes Payable, Other Payables [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount							$ 20,000
Debt Instrument, Interest Rate, Stated Percentage							10.00%
Note Payable 1 [Member] | Notes Payable, Other Payables [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount							$ 10,000
Debt Instrument, Interest Rate, Stated Percentage							10.00%
Convertible Note 1 [Member] | Convertible Notes Payable [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					8.00%	8.00%
Debt Instrument, Maturity Date					Dec. 26, 2015	Dec. 26, 2015
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares					$ 5	$ 5
Convertible Note 1 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount		$ 50,000		$ 50,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.10		$ 0.10
Warrants, Term of Warrants		3 years
Class of Warrant or Rights, Granted (in Shares) | shares		50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.125		$ 0.125
Warrants, Fair Value of Warrants, Granted		$ 3,150
Convertible Note 2 [Member] | Convertible Notes Payable [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					6.00%	6.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares					$ 2	$ 2
Convertible Note 2 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount		$ 25,000		$ 25,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.10		$ 0.10
Warrants, Term of Warrants		3 years
Class of Warrant or Rights, Granted (in Shares) | shares		25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.125		$ 0.125
Warrants, Fair Value of Warrants, Granted		$ 1,575